HOUSTON, Sept. 7,
2022 /PRNewswire/ -- CNS Pharmaceuticals,
Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a
biopharmaceutical company specializing in the development of novel
treatments for primary and metastatic cancers in the brain and
central nervous system, today announced that John Climaco, Chief Executive Officer of CNS
Pharmaceuticals, will present at the H.C. Wainwright
24th Annual Global Investment Conference being held in
New York, NY and virtually on
September 12-14, 2022.
A video webcast of the presentation will be accessible for
viewing on-demand beginning on Monday,
September 12 at 7:00 AM ET for
those registered for the event and will be available on the Events
page in the Investors section of the Company's website
(www.cnspharma.com). The webcast replay will be archived for 90
days following the event.
In addition to the presentation, management will be available to
participate in virtual one-on-one meetings with qualified members
of the investor community who are registered to attend the
conference. For more information, please visit the conference
website.
About CNS Pharmaceuticals,
Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of
its WP1244 drug technology portfolio, which utilizes anthracycline
and distamycin-based scaffolds to create small molecule agents and
is believed to be 500x more potent than daunorubicin in inhibiting
tumor cell proliferation. Preclinical studies of WP1244
demonstrated high uptake in the brain with antitumor activity. CNS
Pharmaceuticals is evaluating the use of the WP1244 portfolio in
the treatment of brain cancers, pancreatic, ovarian, and
lymphomas.
For more information, please visit www.CNSPharma.com, and
connect with the Company on Twitter, Facebook, and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-hc-wainwright-24th-annual-global-investment-conference-301619088.html
SOURCE CNS Pharmaceuticals, Inc.